Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 4/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAP2 | P11137 | 1/20 | 0.50 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040440 | 1.00 | ESR1 (1.00) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL31060913 | 1.00 | ESR1 (1.00) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL7037980 | 0.96 | ESR1 (1.00) | ESR1ESR2PTGS2MAPK14 | |
| SCHEMBL22649305 | 0.89 | ESR1 (0.92) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL13461181 | 0.89 | ESR1 (0.92) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL3864662 | 0.89 | ESR1 (1.00) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL29799621 | 0.89 | ESR1 (1.00) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL7042915 | 0.88 | ESR1 (0.79) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL7038621 | 0.88 | ESR1 (0.79) | ESR1ESR2PTGS2MAPK14KDM4E | |
| SCHEMBL7037982 | 0.88 | ESR1 (0.77) | ESR1ESR2PTGS2MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220377-A1 | Indole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220377-A1 | Indole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885PTGS2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.